Surgery Partners reported Q4 2025 revenue of USD 885.0 million, up 2.4%, and FY 2025 revenue of USD 3.3 billion, up 6.2%. Same-facility revenues rose 3.5% in Q4 and 4.9% in FY, while surgical cases fell 2.1% in Q4 and increased 2.0% in FY. Net loss attributable to shareholders was USD 15.0 million in Q4 and USD 77.9 million in FY. Adjusted EBITDA was USD 156.9 million in Q4, down 4.2%, and USD 526.2 million in FY, up 3.5%. Surgery Partners ended 2025 with USD 239.9 million in cash and cash equivalents and USD 692.8 million of revolving credit facility borrowing capacity; FY operating cash flow was USD 274.3 million. The company issued initial 2026 guidance (excluding M&A) for Adjusted EBITDA of at least USD 530 million and revenue of USD 3.35 billion to USD 3.45 billion. Surgery Partners also announced a new share repurchase program authorized on Feb. 26, 2026, for up to USD 200 million of common stock, and said it is tightening execution and increasing focus on higher-acuity procedures while pursuing organic growth, strategic M&A and portfolio optimization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Surgery Partners Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001638833-26-000006), on March 02, 2026, and is solely responsible for the information contained therein.